Estrogen-Only Hormone Therapy and Alzheimer's: What a New Study Found

For more than twenty years, many women have heard the same short answer about menopausal hormone therapy and the brain: probably risky, better to avoid it. That answer came from real research, but it was never the whole story. A new study from Stanford Medicine, published on August 12, 2026 in the journal Neurology, adds a piece the field had been missing — and it points in a different direction than many people expect.

The study

The researchers wanted to know how menopausal hormone therapy relates to Alzheimer's disease. Not just to diagnoses, which can be imprecise, but to the physical evidence itself: the amyloid plaques and neurofibrillary tangles that define Alzheimer's under a microscope. Those can only be examined properly after death, which is why this kind of study is rare.

The team drew on two existing databases with 21,462 participants in total. Within them, they compared 258 autopsied brains of women who had reported using estrogen-only hormone therapy with those of roughly 2,701 women who had reported no hormone therapy at all. Each brain was scored for the amount and location of plaques and tangles, plus the density of individual plaques. The researchers also checked records from living participants — memory tests, everyday functioning, and biomarkers in blood and spinal fluid — to see whether those told the same story.

What it found

Women who had used estrogen-only therapy had 39% lower odds of receiving a dementia diagnosis during their lifetimes. In the autopsied brains, estrogen-only use was associated with a 35% reduction in the odds of developing Alzheimer's disease. These women also performed better on memory tests and in their ability to manage daily life independently.

The analysis adjusted for age, the APOE4 gene variant, high blood pressure, education, and race. The researchers themselves call the effect modest: smaller than the influence of age, APOE4, or hypertension. What makes it notable is its consistency — it showed up across clinical diagnoses, cognitive tests, and the brain tissue itself.

Why the history matters

If this finding surprises you, there is a reason. In 2003, a large trial called the Women's Health Initiative Memory Study reported that a combined estrogen-plus-progestin therapy appeared to increase dementia risk when started at an older age. Together with findings about breast cancer and heart disease, that report changed medical practice almost overnight. Estimates of lifetime hormone therapy use among women fell from around 27% to below 5%, where they remain today. In 2025, the American drug regulator removed its strongest warning label from these therapies, and the scientific conversation has been slowly reopening since.

The new study looks at something specific: estrogen-only therapy, which is generally prescribed to women who no longer have a uterus. That group is larger than many people realize — by age 60, more than 30% of women have had a hysterectomy.

The honest limits

This is an observational study, not a randomized trial. Women were not assigned to take hormones or not; they and their doctors made those choices decades ago, for their own reasons. That means the study shows an association, and an association is not proof of cause. Something else about the women who chose estrogen therapy could explain part of the difference.

There are other limits worth stating plainly. Hormone use was self-reported. The women in the study were around 70 on average and mostly began therapy later than current practice recommends, under older prescribing patterns. The findings apply only to oral estrogen-only therapy: too few autopsies were available to judge the combined estrogen-plus-progestin form, and topical estrogen was not counted. And assessments of cognitive decline are partly subjective — a point the researchers make themselves. One study, however careful, rarely settles a question with this much conflicting history behind it.

What this means for you

This is not a reason to start hormone therapy in the hope of protecting your memory. No serious researcher is saying that, and neither are we. But if you have had a hysterectomy and are already weighing hormone therapy for menopause symptoms, this study is worth bringing into the conversation with your doctor, alongside your personal risks — breast cancer history, heart health, and clotting risk all belong in that decision.

And whatever you decide about hormones, the factors with the strongest evidence remain the everyday ones: sleep, movement, blood pressure, hearing, and staying socially connected. Those carry most of the weight, for every brain.

One quiet way to stay engaged with your own thinking is to give it a little structured attention each day. That is what Treeny is built for: short daily exercises for memory, focus, and mental speed, guided by Flo, your coach, who adjusts the difficulty to where you are today. Not a treatment, not a promise — just a calm way to keep your mind active and notice how it changes over time.

This article is for general information only and is not medical advice. Hormone therapy has real risks and benefits that differ from person to person. Always discuss decisions about hormone therapy, memory concerns, or any treatment with your doctor or another qualified health professional.